XellSmart Pharmaceutical (XellSmart) has secured US FDA and China NMPA clearance to initiate Phase I/II registrational clinical trials for its off-the-shelf, allogeneic, universal iPSC-derived neuron progenitor cell therapy targeting Multiple System Atrophy–Parkinsonian Type (MSA-P). This marks the company’s fourth consecutive FDA-NMPA trial clearance, following approvals for its iPSC-derived cell therapies for Parkinson’s disease (PD), Spinal Cord Injury (SCI) and Amyotrophic Lateral Sclerosis (ALS).

MSA-P is a rare and fatal neurodegenerative disorder recognised by the World Health Organisation, characterised by progressive Parkinsonian symptoms such as bradykinesia, rigidity and gait disturbances, along with severe autonomic dysfunction. The disease is driven by abnormal α-synuclein aggregation in oligodendrocytes, leading to rapid neuronal degeneration. Median survival after diagnosis is estimated at six to ten years. Currently, no approved therapy worldwide can effectively slow or reverse disease progression.

XellSmart’s investigational therapy aims to regenerate dopamine secretion and promote neural circuit and brain environment repair, offering a potential disease-modifying approach. The programme builds on the company’s growing expertise in CNS-focused iPSC-derived cell therapies, with nine INDs cleared by US and Chinese regulators for Phase I/II trials.

The company’s pipeline includes ongoing registrational studies for Parkinson’s disease in China and the US, including China’s first randomised, double-blind, controlled trial of universal cell therapy for early-onset PD. Additional trials are underway for spinal cord injury and ALS, including an iPSC-derived therapy that received US FDA Orphan Drug Designation in 2023.

Preliminary results from PD registrational trials conducted at leading neurological centres in China have shown encouraging safety outcomes and positive trends in motor function improvement. Patients demonstrated extended ‘ON state’ duration, reduced ‘OFF state’ time and improved daily mobility, alongside imaging evidence suggesting survival and functional integration of transplanted dopaminergic neurons.

Since its establishment in 2021, XellSmart has advanced rapid clinical development supported by consecutive funding rounds led by prominent venture capital firms. The company is simultaneously scaling GMP-grade manufacturing capabilities and quality systems to support future commercialisation of its universal, off-the-shelf iPSC-derived cell therapies.

The latest regulatory clearances further strengthen XellSmart’s position in the iPSC-for-CNS space and reinforce investor and regulatory confidence in its platform as it expands into underserved neurodegenerative indications such as MSA-P.